Randomized trial of GnRHa to protect ovarian function in women undergoing chemotherapy for breast cancer

Studies of the use of gonadotropin-releasing hormone analogs (GnRHa) to protect ovarian function have shown mixed results. A randomized clinical study at two centers in China found that among premenopausal women receiving neoadjuvant or adjuvant chemotherapy for operable breast cancer, gonadotropin-releasing hormone analogs protected the ovarian function, with premature ovarian insufficiency rates of 10.3% in the GnRHa group versus 44.5% in the control group (visual abstract). Post hoc analysis showed that among the patients younger than 35 years of age, the tumor-free survival was also better in the GnRHa group than in the control group (93% versus 62% at 60 months; HR 0.15; p=0.03).